American Medical Association

NATICK, Mass., Oct. 24, 2024 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory Analyses (PLA) code 0523U from the American Medical Association (AMA) for their FDA approved oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal™ CDx is a NGS based IVD kit that uses Pillar's proprietary SLIMamp (Stem-Loop Inhibition-Mediated amplification) technology for detection of single nucleotide variants (SNVs), insertions and deletions in 22 genes using DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens. oncoReveal™ CDx has been FDA cleared on the Illumina MiSeq™ Dx. The oncoReveal™ CDx assay kit is intended to provide pan-cancer tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for previously diagnosed cancer patients with solid malignant neoplasms. oncoReveal™ CDx has also been approved as a companion diagnostic to identify patients who may benefit from EGFR TKI therapy (class approval) in NSCLC and ERBITUX® and VECTIBIX® for KRAS in CRC. "We are proud of achieving this milestone in the launch of oncoReveal™ CDx, which was the first FDA PMA-approved multi-cancer IVD kit launched in the market," said Brian Wright, Chief Marketing Officer of Pillar Biosciences. "In partnership with Illumina, we have enabled rapid and affordable NGS testing to be performed locally in any NGS lab. We are committed to developing and bringing highly accurate, actionable, and reimbursable NGS testing to clinical laboratories and biopharmaceutical companies to help improve treatment decisions and deliver outcomes that are accessible to everyone, everywhere." About Pillar Biosciences Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn. SOURCE Pillar Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, today announced the American Medical Association (AMA) has issued new CPT® medical codes applicable to all Vivos CARE oral medical devices, which will become effective January 1, 2025. Vivos Chairman and CEO, Kirk Huntsman, stated, “This is exciting news for OSA patients and medical providers who treat sleep breathing disorders. Our CARE oral medical devices are the only ones cleared by the U.S. Food and Drug Administration for the treatment of moderate to severe OSA, and these new medical codes will now facilitate coverage and reimbursement by commercial medical insurance payers. From Vivos’ perspective, we believe this will enable a larger number of patients from most demographics to access our breakthrough, proprietary airway remodeling technology and more effectively treat their OSA. This development comes at an opportune moment for Vivos as our recent regulatory approvals, coupled with our new alliance-based marketing and distribution model and now these new codes put Vivos in an improved position to drive revenue growth.” AMA Introduces 420 Updates in CPT® 2025, Including New Codes for Vivos In a recent press release, the AMA explained, “The emergence of medical innovations, new technologies and cutting-edge procedures spurred most of the annual changes presented in the release of the Current Procedural Terminology (CPT®) 2025, the nation’s uniform data-sharing code set for medical procedures and services. There are 420 overall updates in the CPT® 2025 code set, including 270 new codes, 112 deletions, and 38 revisions.” “The CPT® code set is the foundation for the efficient and effective exchange of standardized information in a data-driven health system…with the goal of delivering better patient care, improved outcomes and lower costs,” said AMA President Bruce A, Scott, M.D. “The latest updates to the CPT® code set reflect advancements in contemporary clinical practice.” Mr. Huntsman concluded, “This AMA approval represents our latest regulatory and reimbursement milestone, following another important approval Vivos received for Medicare coverage just a few months ago. As part of our mission, Vivos has worked to make its innovative OSA treatment protocols available to more people so they can improve their lives. With these new CPT® codes, we are taking a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17. This approval highlights our commitment to ensuring more people can receive the care they need while receiving greater support from their healthcare insurance plans.” About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and children. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical, and cost-effective solution for treating mild to severe OSA in adults and moderate to severe OSA in children. It has proven effective in over 45,000 patients treated worldwide by more than 2,000 trained dentists. The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that alter the size, shape, and position of the jaw and soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances. For more information, visit www.vivos.com. Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, including statements related to the acceptance and reimbursement rates of the new CPT codes. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the results of the CPT Code designations described herein on Vivos’ future revenues and results of operations or the anticipated benefits of the Company’s new marketing and distribution model) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all or maintain its Nasdaq listing and (v) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Vivos Investor Relations Contact: Bradford Amman, CFOinvestors@vivoslife.com

COLUMBUS--( BUSINESS WIRE )--AndHealth announced today its partnership with Family Health Services of Darke County, a Community Health Center (CHC) with 5 locations in Western Ohio. Through this partnership, Family Health will now offer Whole-Person Specialty Care and specialty pharmacy services in house, including medication infusions. These services help address the specialty care access crisis that is especially challenging to rural communities, where it is common to drive 1-2 hours for care and to face specialist wait lists that are longer than 6 months. By partnering with AndHealth, Family Health will now offer access to an integrated care model that provides convenient, affordable, and high-quality specialty care for rheumatology, dermatology, and neurology alongside comprehensive support for root causes and Social Drivers of Health (SDOH), such as medically tailored meal delivery, support for behavioral health, sleep, movement, remote monitoring, and continuous access to providers and health coaching. In early 2025 patients will also be able to receive medication infusions and fill their specialty prescriptions directly though Family Health’s specialty pharmacy, where affordable specialty medications are available to all patients. AndHealth upholds ambitious benchmarks for partners and patients, including a 94 Net Promoter Score (NPS) for patient satisfaction. Patients will also no longer face long drives or delays, as nine out of 10 patients have their first visit in under just two weeks. “AndHealth is proud to partner with Family Health, who is a trusted source of quality care in Western Ohio,” said Autumn Glover, SVP of Provider + Community Partnerships at AndHealth. “We believe strongly that by closing specialty care gaps and addressing Social Drivers of Health we can make a major difference in the lives of patients living in Darke County.” Expanding Access Across Ohio Family Health has become a foundational partner of AndHealth in Western Ohio under the Ohio Association of Community Health Centers (OACHC) agreement, which creates a statewide Whole-Person Specialty Care model for CHCs and the patients they serve. In June, OACHC and AndHealth established a master agreement that makes statewide adoption of this critical patient service as cost-effective and efficient as possible by leveraging OACHCs deep expertise, membership scale, and best practices. “I’m heartened to see Family Health Services of Darke County benefit from this strategic partnership and to know they will not only offer best-in-class whole-person specialty care for their existing patients, but also expand the incredible impact they are already making on the Darke county community,” said Julie DiRossi-King, CEO of OACHC. Family Health’s Continued Growth Since 1964, Family Health has delivered high quality and affordable care to the people of Darke County and is increasing its impact through an extensive renovation and expansion at its Greenville campus. Family Health continues its focus on growth and community impact by partnering with AndHealth, which maintains key partner benchmarks like a 25% contribution to topline revenue and a >2:1 patient growth ratio. These financial metrics contribute to the expansion of Family Health’s mission and help fund new services. “We are building for the future of Darke County by investing in key partners that care about our mission as deeply as we do," said Jared Pollick, Executive Director of Family Health. “This is an important step forward in improving access to care in our community so we can reduce the burden that chronic illness has on our neighbors and ensure we can continue to build healthy lives together for years to come.” About Family Health Services Family Health is a Federally Qualified Health Center (FQHC) in Greenville, with additional locations in Arcanum, New Madison, and Versailles, offering a wide range of services, including family medicine, pediatrics, dental, eye care, behavioral health, women’s health, internal medicine, and pharmacy services. Established in 1964, FHS focuses on “building healthy lives together” by working toward positive health outcomes for everyone in the communities it serves. About AndHealth AndHealth helps Community Health Centers (CHCs) radically improve access and outcomes in specialty care and specialty pharmacy for patients, while becoming an even larger and more clinically integrated part of our healthcare system. The Whole-Person Community Care Model provides everything CHCs need to deliver in-house specialty care and specialty pharmacy, built for the unique needs of our medically underserved populations. The model provides CHCs with more patients, more clinical capabilities, alignment with health systems, and sustainable reimbursement and funding that restores the integrity of the patient’s medical home and their critical reimbursement model—both having shifted away from CHCs through external specialty referrals and contract pharmacies. In restoring this integrity, CHCs can stretch scarce federal resources to reach more patients with comprehensive services that weren’t possible before and that are desperately needed by patients—tearing down barriers to promote health equity and demonstrating the power of the CHC movement and its unique model of care. Headquartered in Columbus, Ohio, AndHealth is led by former CoverMyMeds co-founder and CEO Matt Scantland and the team that built Ohio’s first healthcare technology unicorn, by dedicating their lives to collaborative innovation that improves access for patients. AndHealth is dedicated to helping CHCs become an even larger and more successful part of our healthcare system. AndHealth is supported by key investors including the American Medical Association’s innovation subsidiary, Francisco Partners, and the state of Ohio’s economic development organization.